{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:23:36Z","timestamp":1777868616500,"version":"3.51.4"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,27]],"date-time":"2027-02-27T00:00:00Z","timestamp":1803686400000},"content-version":"am","delay-in-days":302,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.canlet.2026.218385","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:14:12Z","timestamp":1772151252000},"page":"218385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PPAR\u03b4: An underappreciated tumor accelerator in pancreatic ductal adenocarcinoma"],"prefix":"10.1016","volume":"645","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9090-8466","authenticated-orcid":false,"given":"Danping","family":"Niu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9238-8046","authenticated-orcid":false,"given":"Daoyan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-0650","authenticated-orcid":false,"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1875-3962","authenticated-orcid":false,"given":"James C.","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imad","family":"Shureiqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8593-1132","authenticated-orcid":false,"given":"Xiangsheng","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218385_bib1","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218385_bib2","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218385_bib3","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.canlet.2026.218385_bib4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218385_bib5","first-page":"77","article-title":"The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma, nature reviews","volume":"9","author":"Samuel","year":"2011","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2026.218385_bib6","first-page":"2969","article-title":"Progression model for pancreatic cancer","volume":"6","author":"Hruban","year":"2000","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2026.218385_bib7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/MPA.0000000000002027","article-title":"Incidence of pancreatic intraepithelial neoplasia in an autopsy series","volume":"51","author":"Longnecker","year":"2022","journal-title":"Pancreas"},{"key":"10.1016\/j.canlet.2026.218385_bib8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/MPA.0000000000000786","article-title":"The prevalence and clinicopathological characteristics of high-grade pancreatic intraepithelial neoplasia: autopsy study evaluating the entire pancreatic parenchyma","volume":"46","author":"Matsuda","year":"2017","journal-title":"Pancreas"},{"key":"10.1016\/j.canlet.2026.218385_bib9","first-page":"1103","article-title":"Pancreatic intraepithelial neoplasms in the normal appearing pancreas: on their precise relationship with age","volume":"55","author":"Ito","year":"2008","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.canlet.2026.218385_bib10","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/01.MP.0000087422.24733.62","article-title":"Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma","volume":"16","author":"Andea","year":"2003","journal-title":"Mod. Pathol. : an official journal of the United States and Canadian Academy of Pathology, Inc"},{"key":"10.1016\/j.canlet.2026.218385_bib11","first-page":"457","article-title":"Early detection of pancreatic cancer using DNA-based molecular approaches, nature reviews","volume":"18","author":"Singhi","year":"2021","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2026.218385_bib12","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.gastro.2011.12.042","article-title":"Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia","volume":"142","author":"Kanda","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2026.218385_bib13","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1053\/j.gastro.2013.01.071","article-title":"Roles for KRAS in pancreatic tumor development and progression","volume":"144","author":"di Magliano","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2026.218385_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113339","article-title":"The role of PPAR-\u03b4 in metabolism, inflammation, and cancer: many characters of a critical transcription factor","volume":"19","author":"Liu","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218385_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.pharmthera.2009.12.001","article-title":"Peroxisome proliferator-activated receptor beta\/delta (PPARbeta\/delta) acts as regulator of metabolism linked to multiple cellular functions","volume":"125","author":"Wagner","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2026.218385_bib16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(03)00269-1","article-title":"Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity","volume":"113","author":"Wang","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218385_bib17","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1073\/pnas.0711875105","article-title":"PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis","volume":"105","author":"Barish","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218385_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nm993","article-title":"Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth","volume":"10","author":"Gupta","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218385_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.91419","article-title":"Metastasis regulation by PPARD expression in cancer cells","volume":"2","author":"Zuo","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218385_bib20","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1172\/JCI27955","article-title":"PPAR delta: a dagger in the heart of the metabolic syndrome","volume":"116","author":"Barish","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218385_bib21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2337\/db07-1318","article-title":"Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men","volume":"57","author":"Ris\u00e9rus","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.canlet.2026.218385_bib22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1161\/01.ATV.0000252790.70572.0c","article-title":"Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist","volume":"27","author":"Sprecher","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.canlet.2026.218385_bib23","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1161\/ATVBAHA.112.247890","article-title":"Lipid effects of peroxisome proliferator-activated receptor-\u03b4 agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome","volume":"32","author":"Olson","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.canlet.2026.218385_bib24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.atherosclerosis.2011.10.029","article-title":"Effects of the PPAR-\u03b4 agonist MBX-8025 on atherogenic dyslipidemia","volume":"220","author":"Choi","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.canlet.2026.218385_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju052","article-title":"Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-delta\/beta overexpression","volume":"106","author":"Zuo","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2026.218385_bib26","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1038\/s41467-022-30392-7","article-title":"Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPAR\u03b4","volume":"13","author":"Liu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218385_bib27","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1158\/0008-5472.CAN-18-1790","article-title":"Pleiotropic effects of PPARD accelerate colorectal tumorigenesis, progression, and invasion","volume":"79","author":"Liu","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218385_bib28","first-page":"4480","article-title":"PPAR\u03b4 mediates the effect of dietary fat in promoting colorectal cancer metastasis","volume":"79","author":"Wang","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218385_bib29","doi-asserted-by":"crossref","first-page":"12890","DOI":"10.1073\/pnas.0705505104","article-title":"Transcriptional network governing the angiogenic switch in human pancreatic cancer","volume":"104","author":"Abdollahi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218385_bib30","doi-asserted-by":"crossref","first-page":"13275","DOI":"10.1073\/pnas.97.24.13275","article-title":"Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer","volume":"97","author":"Gupta","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218385_bib31","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1165\/rcmb.2007-0426OC","article-title":"Peroxisome proliferator-activated receptor beta\/delta expression and activation in lung cancer","volume":"39","author":"Pedchenko","year":"2008","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.canlet.2026.218385_bib32","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1158\/0008-5472.CAN-13-0322","article-title":"PPAR\u03b4 induces estrogen receptor-positive mammary neoplasia through an inflammatory and metabolic phenotype linked to mTOR activation","volume":"73","author":"Yuan","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218385_bib33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1053\/j.gastro.2019.03.018","article-title":"PPARD and interferon gamma promote transformation of gastric progenitor cells and tumorigenesis in mice","volume":"157","author":"Zuo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2026.218385_bib34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1541-7786.MCR-19-0895","article-title":"PPAR\u03b4 interacts with the hippo coactivator YAP1 to promote SOX9 expression and gastric cancer progression","volume":"18","author":"Song","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218385_bib35","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/jnci\/djp078","article-title":"Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis","volume":"101","author":"Zuo","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2026.218385_bib36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejphar.2018.10.050","article-title":"PPAR\u03b4 agonist enhances colitis-associated colorectal cancer","volume":"842","author":"Zhou","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218385_bib37","doi-asserted-by":"crossref","first-page":"7084","DOI":"10.1073\/pnas.1324233111","article-title":"Peroxisome proliferator-activated receptor \u03b4 promotes colonic inflammation and tumor growth","volume":"111","author":"Wang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218385_bib38","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-24-3475","article-title":"PPAR-\u03b4 orchestrates a pro-metastatic metabolic response to microenvironmental cues in pancreatic cancer","author":"Parejo-Alonso","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218385_bib39","volume":"2013","author":"Coleman","year":"2013"},{"key":"10.1016\/j.canlet.2026.218385_bib40","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1158\/2159-8290.CD-22-0661","article-title":"A cancer cell-intrinsic GOT2-PPAR\u03b4 axis suppresses antitumor immunity","volume":"12","author":"Abrego","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218385_bib41","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218385_bib42","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218385_bib43","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ccr.2007.01.012","article-title":"Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice","volume":"11","author":"Guerra","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218385_bib44","doi-asserted-by":"crossref","first-page":"6359","DOI":"10.1158\/0008-5472.CAN-13-1558-T","article-title":"Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance","volume":"73","author":"Zhang","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218385_bib45","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/0008-5472.CAN-11-0908","article-title":"STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis","volume":"71","author":"Corcoran","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218385_bib46","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41419-024-06930-0","article-title":"Emerging mechanisms and promising approaches in pancreatic cancer metabolism","volume":"15","author":"Wu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218385_bib47","article-title":"Pancreatic cancer, nature reviews","volume":"2","author":"Kleeff","year":"2016","journal-title":"Disease primers"},{"key":"10.1016\/j.canlet.2026.218385_bib48","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/gut.2010.236026","article-title":"Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project","volume":"61","author":"Iacobuzio-Donahue","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2026.218385_bib49","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","article-title":"Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism","volume":"149","author":"Ying","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218385_bib50","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1158\/2159-8290.CD-15-0671","article-title":"Pancreatic cancer metabolism: breaking it Down to build it back up","volume":"5","author":"Perera","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218385_bib51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ccell.2016.12.006","article-title":"Employing metabolism to improve the diagnosis and treatment of pancreatic cancer","volume":"31","author":"Halbrook","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218385_bib52","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia","volume":"21","author":"Pylayeva-Gupta","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218385_bib53","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1158\/1535-7163.MCT-06-0686","article-title":"Tumor-stroma interactions in pancreatic ductal adenocarcinoma","volume":"6","author":"Mahadevan","year":"2007","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218385_bib54","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218385_bib55","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1177\/1534735418794884","article-title":"Cancer-associated fibroblasts in pancreatic cancer: should they be deleted or reeducated?","volume":"17","author":"Qu","year":"2018","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.canlet.2026.218385_bib56","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bbalip.2015.01.008","article-title":"PPAR\u03b4 activation induces hepatic long-chain acyl-CoA synthetase 4 expression in vivo and in vitro","volume":"1851","author":"Kan","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2026.218385_bib57","doi-asserted-by":"crossref","first-page":"16664","DOI":"10.1074\/jbc.M110.112805","article-title":"Long chain acyl-CoA synthetase-3 is a molecular target for peroxisome proliferator-activated receptor delta in HepG2 hepatoma cells","volume":"285","author":"Cao","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218385_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112223","article-title":"Peroxisome proliferator-activated receptor \u03b4 rescues xCT-deficient cells from ferroptosis by targeting peroxisomes","volume":"143","author":"Hwang","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218385_bib59","article-title":"Emerging potential mechanism and therapeutic target of ferroptosis in PDAC: a promising future","volume":"23","author":"Li","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218385_bib60","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","article-title":"Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer","volume":"21","author":"Whatcott","year":"2015","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2026.218385_bib61","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-07-2477","article-title":"Pancreatic stellate cells: partners in crime with pancreatic cancer cells","volume":"68","author":"Vonlaufen","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218385_bib62","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/gut.44.4.534","article-title":"Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis","volume":"44","author":"Apte","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2026.218385_bib63","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218385_bib64","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.0303-6987.2005.00345.x","article-title":"Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors","volume":"32","author":"Nijsten","year":"2005","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.canlet.2026.218385_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21165723","article-title":"PPARs and angiogenesis-implications in pathology","volume":"21","author":"Wagner","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218385_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121623","article-title":"Vascular PPAR\u03b2\/\u03b4 promotes tumor angiogenesis and progression","volume":"8","author":"Wagner","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218385_bib67","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1038\/sj.emboj.7601803","article-title":"Deregulation of tumor angiogenesis and blockade of tumor growth in PPARbeta-deficient mice","volume":"26","author":"M\u00fcller-Br\u00fcsselbach","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2026.218385_bib68","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218385_bib69","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.tem.2015.09.004","article-title":"Establishing the role of PPAR\u03b2\/\u03b4 in carcinogenesis","volume":"26","author":"Peters","year":"2015","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.canlet.2026.218385_bib70","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/me.2007-0190","article-title":"Identification and characterization of a selective peroxisome proliferator-activated receptor beta\/delta (NR1C2) antagonist","volume":"22","author":"Shearer","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.canlet.2026.218385_bib71","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/cmdc.201100408","article-title":"Development of improved PPAR\u03b2\/\u03b4 inhibitors","volume":"7","author":"Toth","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.canlet.2026.218385_bib72","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/emmm.201302666","article-title":"Src is activated by the nuclear receptor peroxisome proliferator-activated receptor \u03b2\/\u03b4 in ultraviolet radiation-induced skin cancer","volume":"6","author":"Montagner","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.canlet.2026.218385_bib73","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.4161\/cbt.8.13.8691","article-title":"A novel peroxisome proliferator-activated receptor delta antagonist, SR13904, has anti-proliferative activity in human cancer cells","volume":"8","author":"Zaveri","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2026.218385_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108693","article-title":"Peroxisome proliferator-activated receptor antagonists as emerging therapeutics in cancer treatment","volume":"163","author":"Misal","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.canlet.2026.218385_bib75","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1021\/jm900464j","article-title":"Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist","volume":"53","author":"Shearer","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2026.218385_bib76","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/mol.110.065508","article-title":"Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta\/delta antagonist GSK3787","volume":"78","author":"Palkar","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218385_bib77","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s10120-023-01418-w","article-title":"PPAR\u03b4 dysregulation of CCL20\/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment","volume":"26","author":"Liu","year":"2023","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.canlet.2026.218385_bib78","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1124\/mol.111.074039","article-title":"High-affinity peroxisome proliferator-activated receptor \u03b2\/\u03b4-specific ligands with pure antagonistic or inverse agonistic properties","volume":"80","author":"Naruhn","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218385_bib79","doi-asserted-by":"crossref","first-page":"8794","DOI":"10.1038\/ncomms9794","article-title":"Saturated fatty acids regulate retinoic acid signalling and suppress tumorigenesis by targeting fatty acid-binding protein 5","volume":"6","author":"Levi","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218385_bib80","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1038\/onc.2012.549","article-title":"Inverse PPAR\u03b2\/\u03b4 agonists suppress oncogenic signaling to the ANGPTL4 gene and inhibit cancer cell invasion","volume":"32","author":"Adhikary","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218385_bib81","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/jm2017122","article-title":"(Z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile (DG172): an orally bioavailable PPAR\u03b2\/\u03b4-selective ligand with inverse agonistic properties","volume":"55","author":"Lieber","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2026.218385_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102429","article-title":"KRAS mutation dictates the cancer immune environment in pancreatic ductal adenocarcinoma and other adenocarcinomas","volume":"13","author":"Gu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218385_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15205015","article-title":"Targeting KRAS in pancreatic ductal adenocarcinoma: the long road to cure","volume":"15","author":"de Jesus","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218385_bib84","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/bs.pmbts.2016.09.008","article-title":"Molecular pathogenesis of pancreatic cancer","volume":"144","author":"Grant","year":"2016","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/j.canlet.2026.218385_bib85","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","article-title":"A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer","volume":"30","author":"Wei","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218385_bib86","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218385_bib87","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218385_bib88","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1101\/gad.351037.123","article-title":"Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer","volume":"37","author":"Han","year":"2023","journal-title":"Gene Dev."},{"key":"10.1016\/j.canlet.2026.218385_bib89","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/2159-8290.CD-19-0597","article-title":"Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer","volume":"10","author":"Hou","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218385_bib90","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nature13611","article-title":"Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function","volume":"514","author":"Viale","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218385_bib91","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s43018-023-00702-z","article-title":"Lipids as mediators of cancer progression and metastasis","volume":"5","author":"Vogel","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2026.218385_bib92","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.cmet.2022.09.023","article-title":"The role of lipids in cancer progression and metastasis","volume":"34","author":"Martin-Perez","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.canlet.2026.218385_bib93","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1158\/1541-7786.MCR-17-0061","article-title":"PPAR\u03b4 reprograms glutamine metabolism in sorafenib-resistant HCC","volume":"15","author":"Kim","year":"2017","journal-title":"Mol. Cancer Res. : MCR"},{"key":"10.1016\/j.canlet.2026.218385_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/science.ads0239","article-title":"A neomorphic protein interface catalyzes covalent inhibition of RAS(G12D) aspartic acid in tumors","volume":"389","author":"Weller","year":"2025","journal-title":"Science"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526001485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526001485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:13:01Z","timestamp":1777551181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526001485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":94,"alternative-id":["S0304383526001485"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218385","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PPAR\u03b4: An underappreciated tumor accelerator in pancreatic ductal adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218385"}}